Get Easy Health Digest™ in your inbox and don’t miss a thing when you subscribe today. Plus, get the free bonus report, Mother Nature’s Tips, Tricks and Remedies for Cholesterol, Blood Pressure & Blood Sugar as my way of saying welcome to the community!
As the COVID-19 crisis continues on for an unforeseen amount of time, scientists all over the world are scrambling to find a treatment that works.
We’ve had a few false hopes so far… like the anti-malarial drugs chloroquine and hydroxychloroquine, which recent evidence shows are not only ineffective but dangerous.
Now, however, it looks like the treatment we’ve been waiting for may finally be upon us.
New research from the University of Alberta shows that a drug originally designed to treat Ebola and effectively used to treat the coronavirus Middle East Respiratory Syndrome (MERS) could stop COVID-19 from replicating… which means it could prevent thousands and thousands of people from getting seriously ill or even dying.
Remdesivir prevents COVID-19 from replicating
In a recent study published in the Journal of Biological Chemistry, researchers from the University of Alberta found that the drug remdesivir could stop COVID-19 from replicating and becoming severe.
Remdesivir was originally developed in 2014 to fight the Ebola epidemic, and a study conducted in February by the same University of Alberta research team found that the drug works against the Middle East Respiratory Syndrome (MERS) virus, which is also a coronavirus.
In this latest study, researchers found that remdesivir inhibits SARS-CoV-2’s DNA polymerase, which the virus needs to replicate. It does this by replicating the virus’s building blocks and tricking it into incorporating these replications into its DNA.
“These coronavirus polymerases are sloppy and they get fooled, so the inhibitor gets incorporated many times and the virus can no longer replicate,” said Matthias Götte, chair of medical microbiology and immunology at U of A.
This research aligns with previous research in animals and cells showing that remdesivir is a potent antiviral. And all this research combined earned remdesivir the classification of a “direct-acting antiviral” against SARS-CoV-2. It also guarantees that clinical trials will be conducted on the drug. In fact, these clinical trials are already happening across the world because the World Health Organization fast-tracked them. WHO also fast-tracked trials for several other promising drugs. And we should get results from these trials in the next couple of months.
Keep your fingers crossed for an effective new treatment
The good news is, we’re getting closer to a potential treatment for this devastating virus. In fact, Matthias Götte said the amount of research happening and the cooperation between researchers across the world will produce more than one effective treatment for COVID-19 in the months and years to come. So, stay strong, keep social distancing and keep your fingers crossed that these treatments emerge sooner rather than later.
Editor’s Note: If your blood pressure is high and you have blocked arteries, your heart is already working harder than normal compromising lung capacity. That’s how the coronavirus can become a catalyst to a heart attack. Dr. Michael Cutler, M.D., has written the most informative book on hushed up natural heart cures you’ll never hear from your own doctor. Click here for a preview! Plus, you get my 100% Money-back, No-Questions-Asked Guarantee of Satisfaction!
- Study finds remdesivir effective against a key enzyme of coronavirus that causes COVID-19 — University of Alberta Faculty of Medicine & Dentistry
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency — Journal of Biological Chemistry